Although it is considered a relatively rare disorder, veno-occlusive disease (VOD) is one of the main causes of overall, non-relapse mortality associated with haematopoietic stem cell transplantation (HSCT). This article, based on the consensus opinion of haemato-oncology nurses, haemato-oncologists and pharmacists from both adult and paediatric services at the VOD International Multi-Disciplinary Advisory Board at the European Society for Blood and Marrow Transplantation (EBMT) meeting, Istanbul, 2015, aims to explore the multidisciplinary approach to care for the management of VOD, with an emphasis on current challenges in this area. The careful monitoring of HSCT patients allows early detection of the symptoms associated with VOD and timely treatment, ultimately improving patient outcomes. As part of a multidisciplinary team, nurses have an essential role to play, from pretransplant assessment to medical management and overall care of the patient. Physicians and pharmacists have a responsibility to facilitate education and training so that nurses can work effectively within that team.
According to the World Health Organization, more than 50 000 haematopoietic stem cell transplantation (HSCT) procedures are carried out annually worldwide and this figure is increasing each year. Indeed, HSCT has become a standard treatment for many different malignant and non-malignant diseases, but can lead to major early complications (1, 2) . Hepatic veno-occlusive disease (VOD), also known as hepatic sinusoidal obstruction syndrome (SOS), is one of the main causes of non-relapse, transplant-related mortality (NRM) (1, 3, 4) . In a review of 135 studies performed between 1979 and 2007, the overall mean incidence of VOD was 14% (5) . Severe VOD may be fatal if not resolved within 100 d of transplantation (6) , and in the review by Coppell and colleagues (5) , the mortality rate from severe VOD was reported as 84%. Most of those patients developed multi-organ failure (MOF), which was the most common cause of death (5) .
The pathogenesis of VOD is not completely understood (1) , but experimental models have shown that toxic metabolites cause endothelial injury, which is followed by loss of fenestrae in sinusoidal endothelial cells (SEC), formation of gaps within and between SEC and rounding up or swelling of SEC. Thus, red blood cells penetrate into the space of Disse and dissect the sinusoidal lining cells, which embolise downstream and block the sinusoids, reducing the hepatic venous outflow and producing postsinusoidal hypertension (7) . Clinically, VOD is characterised by features such as hepatomegaly, jaundice, weight gain and ascites (8, 9) .
The VOD International Multi-Disciplinary Advisory Board at the Istanbul 2015 European Society for Blood and Marrow Transplantation (EBMT) meeting recognised that, despite its contribution to overall NRM, VOD is considered a relatively rare disorder; hence, nursing education surrounding VOD is currently suboptimal. New haemato-oncology nurses are expected to be particularly in need of education about this condition. This article is based on the consensus opinion of haemato-oncology nurses, haemato-oncologists and pharmacists from both adult and paediatric services. At the International Advisory Board meeting, the aim was to explore the multidisciplinary approach to care for the management of VOD, with an emphasis on current challenges in this area. The recent position statement from the EBMT (7) has emphasised that in order for VOD to be successfully prevented, identified, diagnosed and treated, multidisciplinary team work is essential and nurses should receive specific education on VOD to understand the importance of their role in the team in relation to early detection and intervention.
The development of VOD depends on the interaction of risk factors, which are patient-, disease-and treatmentrelated; some risk factors are also specific to paediatric patients (see Table 1 ).
Because accurate and timely recognition of VOD is essential for the initiation of appropriate treatment (10) , haematooncology nurses should be familiar with the risk factors and non-specific clinical signs and symptoms of VOD so that patients can be monitored closely for its occurrence (11) .
There are some controversial issues with regard to VOD risk factors (e.g. role of iron overload, whether all second allogeneic HSCT should be considered as high risk or only myeloablative second allogeneic HSCT, whether there should be a threshold below which busulfan (BU)-based conditioning regimen should no longer be considered as a risk factor), and these have recently been discussed by Mohty et al. (7) .
The role of nurses in identifying and managing VOD
Nurses play an essential role in assessing and monitoring HSCT recipients and providing supportive care (11) . Although there may be national, or even local, differences in nurses' authority and remit, it is important not to simply execute, but to understand why various assessments are being carried out and what they signify. Nursing patients undergoing HSCT includes assessing risk, conducting baseline measurements, monitoring changes, recognising signs and symptoms leading to the diagnosis of VOD, and managing care appropriately. At-risk patients must be identified pretransplant. Therefore, starting in the ambulatory setting, the entire team should work together to identify high-risk patients. It is important for nurses to be aware of all the risk factors before transplantation (see Table 1 ). Thus, all possible supportive or treatment measures can be established prior to transplant.
Nurses should be particularly proactive with those patients identified as high risk, to identify complications promptly, as early detection is critically important to the overall outcome. The findings should be documented and the team alerted at the earliest suspicion of complications.
The measurements that should be performed at baseline, according to the patient's risk category, are listed in Table 2 .
It is pivotal to recognise complications early and manage those appropriately without delay, in an attempt to avoid the onset of late signs, such as bleeding, abnormal liver function tests, pulmonary failure or MOF; everyone is responsible, and the multidisciplinary approach to care has been identified as a key enabler in the provision of high-quality treatment and care in oncology (12, 13) . It is generally considered that the peak incidence of VOD occurs around Day 12 (post-transplant). In a recently published phase III trial, the median time to VOD/SOS diagnosis post-HSCT in adults was 13 d in the defibrotide group (range, 1-25) and 11 d in the historical control group (range, 4-19) (14) and the median onset of VOD was Day 14 in paediatric HSCT recipients (15) .
The early stage of VOD (or 'mild' VOD) may be very common, but this is not well recognised, as the symptoms are self-limiting and may not require treatment. Therefore, it is important for nurses to learn to identify 'mild' VOD before it becomes moderate, with evidence of liver injury and requiring analgesics, diuretics and other supportive care, or severe, with associated MOF and very high mortality (5) . Increase in weight is a subtle sign that typically develops in the early stages of VOD (16) . Similarly, right upper quadrant pain (RUQ) and abdominal pain are early signs, and all are part of the established Seattle and Baltimore criteria (17, 18) . Platelet refractoriness may also be observed, especially in children, but this is not usually one of the recognised early signs (19, 20) . Establishing the diagnosis of VOD is often problematic in clinical practice, and the currently used criteria have certain limitations, the most important of which being the lack of sensitivity and specificity, which is an impediment to earlier diagnosis and treatment of VOD (7) .
It should be mentioned that the Seattle and Baltimore criteria have been used in clinical practice, research studies and trials for the past three decades (6, 15) with only minor modifications during this period (15, 18, 21) . However, it has been suggested (22) that, whilst these criteria were acceptable in an era when the available treatment was restricted and carried substantial toxic effects, and early intervention did not elicit any apparent clinical benefit Getting an accurate measurement of abdominal girth is often difficult, but it is advised to choose a method (i.e. sitting/standing/lying/a marked line) and stick to it and making sure that the method of measurement is documented clearly in the nursing notes so that any changes in girth can be considered in context. (23) (24) (25) (26) , they may no longer be justifiable. Treatment options are now available, and data show that early intervention is reasonable and effective (6) . Furthermore, whereas current VOD definitions apply to both adults and children, the clinical presentation of this complication differs between these two patient populations and distinct diagnostic criteria for adults and children would seem to be mandatory. A recent proposal which focuses on new criteria for adult patients only has been published, although this has yet to be prospectively validated in clinical studies (22) , and a similar paper focused on children is in preparation.
Stringent monitoring for the occurrence of VOD includes important nursing responsibilities, such as accurate record of fluid intake and output, and recording daily weight (11) . The recommended monitoring assessments of a patient's status relative to their baseline measurements include weight (define threshold of >5%), abdominal girth, inspection of skin, sclera and abdomen, fluid balance, bleeding and bruising, blood tests [daily laboratory values, particularly liver enzymes, serum bilirubin and serum creatinine (trend in values over several days)] (11), respiratory signs and symptoms, and pain levels and location of pain. HSCT recipients will generally be monitored for all these aspects, except for specific assessments of abdominal girth, RUQ pain and inspection of sclera, which are conducted in high-risk patients. Standard-risk patients should be monitored at least once daily and high-risk patients at least twice daily. In both cases, patient and caregivers should be given early warning of even minimal changes.
Assessing respiratory and neurological symptoms is often part of the general nursing assessment; hence, respiratory rates, oxygen saturations and neurological changes (such as confusion) should be recorded. In addition, knowledge of the relevant reference ranges of daily blood tests will enable nurses to be proactive in the event of a significant change in value trends. Some centres also record the location, nature and degree of pain at least once every shift. Furthermore, even if bleeding is not an early symptom of VOD and thus cannot be used for early identification of this condition, it is part of the general nursing assessment, and it is therefore necessary to educate patients to be proactive so that they are able to inform the medical team if they notice any visible bleeding.
With regard to recording daily weight, it should be preagreed what level and pattern of weight gain represent a clinical concern. This is also dependent on the diagnosis criteria applied in the institutions, as there is a discrepancy between the modified Seattle criteria of McDonald et al. More recently, the institutions increasingly agree on the modified Seattle criteria, but adopting the >5% weight gain from the Baltimore criteria. However, the recently published proposal for new criteria for adult patients considers that a weight increase ≥5% and <10% should be considered as default criterion for moderate VOD (if no other criteria are fulfilled) and severe VOD (if any other criteria are met) (22) .
An accurate fluid balance (accurately monitoring the fluids going in and out) is probably one of the most important aspects of a nurse's monitoring role. Fluid imbalance is one of the earliest signs of VOD. It should be measured very carefully and cumulatively so that the medical team is aware of the trend over a period of 24 h. A fluid imbalance refractory to diuretics represents an early sign of endothelial damage and 'third spacing'.
Monitoring blood count results (platelets, in particular) and electrolytes can be a nursing task because nurses are the ones who are most likely to take blood samples and see the results first; hence, they can promptly alert medical colleagues if there is a problem.
Communication and collaboration between team members are vital. In the multidisciplinary team, every profession has its responsibilities and nurses should notify the physician at the earliest suspicion of VOD, before it becomes moderate in severity.
The diagnosis of VOD is largely one of exclusion, as the signs and symptoms are also indicative of other conditions. For example, rapid weight gain is also present in congestive heart failure (CHF), renal failure, sepsis syndrome and capillary leak syndrome; hepatomegaly and ascites are also features of CHF, fungal infection, Epstein-Barr virus lymphoproliferative disease, pancreatitis and portal vein thrombosis; jaundice is also present in biliary infection, acute graft-vs.-host disease, cholestasis, haemolysis, or with drug or total parenteral nutrition injury, and cyclosporine treatment (27) .
The recommended actions to take in cases of suspected and confirmed cases of VOD are listed in Table 2 .
Managing VOD: principles and challenges
Treatment of VOD may be categorised into preventive measures and treatment with curative intention (7) . There is currently no standard preventive strategy for VOD, but, in general, preventive measures combine two main objectives: address VOD risk factors and provide pharmacological prevention/prophylaxis. However, high-level evidence from randomised controlled trials supporting prophylaxis for VOD is scarce (1), but owing to the life-threatening nature of VOD, any preventive measures which have the potential to reduce its incidence and/or severity in patients at high risk should be considered (28) . With regard to curative treatment, in addition to symptomatic treatment with supportive care, the only proven curative treatment for VOD at present is defibrotide.
Preventive measures
According to Johnson and Savani (29) , preventive measures could include appropriate conditioning regimen selection, avoiding hepatotoxic drugs and aggressive fluid management. There is some evidence that suggests a benefit for prevention with ursodiol; however, the results have not been confirmed by all studies (30) .
Despite the fact that most patient-and hepatic-related risk factors are impossible to reverse, and that the benefits of VOD prophylaxis in adults are inconclusive, it is still recommended that at-risk patients should be included in prophylactic programmes whenever possible (7, 28) .
Transplant-and treatment-related risk factors are easier to address (7, 28) . For example, the use of reduced-intensityconditioned HSCT has reduced the incidence of VOD (3), and, at present, this modality of HSCT provides comparable results with those of myeloablative-conditioned (MAC) HSCT for many diseases (28) . It is also possible to reduce the toxicity of MAC using the combination of intravenous (IV) BU and fludarabine instead of the classical oral BU and cyclophosphamide (CY) (31) .
With regard to pharmacological measures to prevent VOD, a prospective phase 3 study noted reduced incidence of VOD in paediatric HSCT patients who received prophylaxis with defibrotide (15), but defibrotide is not approved for prophylactic treatment in any age group, and there are no randomised studies of prophylaxis with defibrotide in adult patients (7) . Other options, such as the use of heparin, remain controversial: a meta-analysis of 12 studies did not find a significant beneficial effect of anticoagulation prophylaxis (32) . Similarly, the evidence for the usefulness of ursodeoxycholic acid for VOD prevention is non-conclusive (33) (34) (35) (36) (37) (38) . A recent Cochrane systematic review (4) reported that there was lowor very low-quality evidence that ursodeoxycholic acid might reduce the incidence of hepatic VOD, all-cause mortality and mortality due to VOD in HSCT recipients and that there was insufficient evidence to support the use of heparin, low-molecular-weight heparin, defibrotide, glutamine, fresh frozen plasma, antithrombin III or prostaglandin E 1 .
Curative treatment
The first step is symptomatic treatment with supportive care, which traditionally has been a crucial part of the treatment plan (1, 11, 27, 39, 40) , and nurses play a key role in providing this (11) .
Supportive therapy must be initiated as soon as possible; fluid and sodium balance and the careful use of diuretics, as well as avoidance of hepatotoxic medications, should be introduced at the first suspicion of VOD (1, 28) . It should be noted that avoidance of hepatotoxic medications is challenging, as some of the agents that are considered hepatotoxic are drugs that are administered as part of the transplant regimen (e.g. methotrexate, cyclosporine). Paracetamol should be avoided for pain relief due to its toxicity.
Several symptomatic measures can be used to reduce the discomfort produced by massive ascites or pleural effusions, starting with oxygen therapy, in conjunction with analgesia, paracentesis and thoracentesis, as appropriate (28, 39) . In cases where fluid accumulation and renal failure cannot be controlled, haemodialysis/haemofiltration is necessary (28, 39, 41) .
In addition to these symptomatic measures, the only proven curative treatment for VOD at present is defibrotide, which was approved in 2014 in Europe for the treatment of severe VOD after HSCT (7) .
Defibrotide is a polydisperse oligonucleotide with local antithrombotic, anti-ischaemic and anti-inflammatory activity, which has protective effects on the small vessel endothelium. Its mechanism of action in VOD remains to be elucidated, but this appears to involve two distinct elements: the protection of endothelial cells and restoration of the thrombotic-fibrinolytic balance (42, 43) . Defibrotide is an IV medication prescribed at a recommended dose of 6.25 mg/kg body weight every 6 h (25 mg/kg/d), over a 2-h infusion. The recommended final concentration of defibrotide is 4-20 mg/mL, but this can represent a challenge in fluid-restricted patients. It is recommended that defibrotide is administered for a minimum of 21 d and continued until the symptoms and signs of severe VOD resolve (44) . However, as an IV treatment, it may in rare cases need to be given on an outpatient basis, if applicable according to local routines and resources.
Defibrotide has been shown to improve complete response and survival in patients with severe VOD (42, 43) , and its safety profile is largely favourable, with toxicities comparable with control populations (42) . In contrast, heparin plus recombinant tissue plasminogen activator (rt-PA) is associated with an increased risk of life-threatening bleeding and is not recommended in patients with severe VOD who have already developed MOF (23, 40, 45) .
Current practical challenges
There are several challenges being faced by a nurse who is monitoring post-HSCT patients. Traditionally, the patient's abdominal girth is recorded upon admission and used as a baseline for comparison (27) , but it is not always easy to obtain these measurements. Sometimes, patients are so sick that they cannot be safely moved and there is also great variability in terms of location of measurement, making the measurements unreliable. Abdominal girth measurement may be easier to obtain in children, as they are easier to manoeuvre, but the same limitations apply in terms of variability of location. In addition, the comfort of the patient, including positioning and pain relief, is a nursing challenge as ascites can make it difficult to position patients in a comfortable way for administration of blood products, electrolytes and any other treatment that they may need (27) .
Another practical challenge for nurses is effective delivery of drugs, in different situations. Balancing the need to administer drugs in patients whose fluids need to be restricted, due to the ascites associated with VOD, can be difficult. Nurses need to know the smallest volumes that may be safely delivered and how the most appropriate analgesics should be administered. Close communication with physicians and pharmacists on the team regarding medical orders and drug administration will enable nurses to meet these challenges.
Not least of the challenges is that of evaluating and managing the patients' psychological well-being and that of their family and carers, in the light of this potentially lifethreatening condition (11) . Nurses can educate patients and their families about VOD, its treatment and supportive care (11) , promoting open communication and discussion, as well as allowing time to express worries and concerns. Other healthcare professionals in the team should be involved in the psychological support, as appropriate.
The importance of the multidisciplinary approach to care
The overwhelming message from the VOD International Multi-Disciplinary Advisory Board was that team work is essential for the diagnosis and management of VOD and that nurses play a crucial role in the multidisciplinary team. Nurses are often recognised as being the most informed about the most up-to-date status of a patient, making them best placed to alert medical colleagues of any deterioration that might require intervention (13) . Moreover, nurses can play a key role in providing clear and accessible verbal and written medical information to patients and carers, in a timely and sensitive manner (13) .
Conclusions
The careful monitoring of HSCT patients allows early detection of the symptoms associated with VOD and timely treatment, ultimately improving patient outcomes. As part of a multidisciplinary team, nurses have an essential role to play, from pretransplant assessment to medical management and overall care of the patient. Hence, there is a need for nurse education in this area, especially for new haematooncology nurses. Physicians have a responsibility to facilitate education and training so that nurses can work effectively with team members of different professions. A learning programme on VOD, to be used in group or selflearning, can be found in the nursing section of the EBMT website.
